CONMED Corp. 10-Q Summary: Quarter Ended June 30, 1999
Business Context and Reporting Period
This Form 10-Q covers the three and six months ended June 30, 1999. CONMED Corporation is a leading developer and manufacturer of medical instruments and systems, including arthroscopic surgery devices, powered surgical instruments, and electrosurgical systems. The company operates as a single segment. As of August 4, 1999, there were 15,294,798 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 1999 | 6 Months Ended June 1999 |
|---|---|---|
| Net Sales | $90,483 | $181,352 |
| Cost of Sales | $42,825 | $86,367 |
| Gross Margin % | 52.7% | 52.4% |
| Operating Income | $18,266 | $36,071 |
| Net Income | $6,690 | $13,013 |
| Diluted EPS | $0.43 | $0.84 |
| Cash from Operations | N/A | $14,447 |
| Cash & Equivalents | $2,519 | $2,519 |
| Total Debt (Current + Long-term) | $369,263 | $369,263 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12.4% for the quarter and 12.8% for the six-month period compared to 1998. Approximately 5% of this increase is attributed to improved pricing from shifting distribution from Zimmer, Inc. to direct sales. The remainder is driven by volume growth from the 3M fluid management acquisition and existing product lines.
- Margin Expansion: Gross margin improved to 52.7% (Q2) and 52.4% (YTD) from 49.2% and 48.8% in the prior year periods, respectively. This is due to higher volumes and the elimination of fixed-price distribution agreements.
- Expense Increases: Selling and administrative expenses rose to 29.3% of sales (Q2) from 27.3% in 1998, primarily due to costs associated with direct selling and new product launches. R&D expenses remained flat in absolute terms but decreased as a percentage of sales.
- Interest Expense: Interest expense increased slightly due to higher borrowings under the revolving credit facility, partially offset by lower term debt balances.
- Extraordinary Items: The six-month period in 1998 included a $1,569,000 (net of tax) extraordinary charge related to the write-off of deferred financing fees from a 1998 debt offering. No such item occurred in 1999.
Outlook, Risks, and Unusual Items
- Acquisition Activity: On June 29, 1999, the company agreed to purchase the Powered Surgical Instrument business of 3M for $39,000,000. The deal closed on August 11, 1999, funded by an amendment to the credit facility adding a $40,000,000 loan commitment.
- Liquidity: Net working capital increased to $97,978,000. The company has $67,000,000 available under its $100,000,000 revolving credit facility. Management believes cash flow and credit facilities are sufficient for operations and debt service.
- Debt Structure: The company holds $130,000,000 in subordinated notes maturing in 2008 at 9.0% interest. Term loans total $205,375,000. Interest rate swaps are in place to fix rates on $100,000,000 of floating debt.
- Risks: Key risks include Year 2000 (Y2K) compliance (though costs are not expected to be material), foreign operations risks (including Euro conversion), and the integration of recent acquisitions. The credit facility contains covenants restricting dividends and additional indebtedness.
Investor Verification Checklist
- Verify the integration progress and revenue contribution of the 3M Powered Surgical Instrument business acquired in August 1999.
- Monitor the impact of the shift from Zimmer distribution to direct sales on long-term gross margins and selling expenses.
- Review the company's ability to meet debt covenants, specifically regarding working capital levels and financial ratios, given the high debt load ($369M+).
- Confirm the status of Year 2000 remediation for critical IT and non-IT systems and third-party vendors.
- Assess the utilization of the $67,000,000 remaining capacity in the revolving credit facility.